Despite strong guidance and pipeline, the stock fell due to ...
Despite strong guidance and pipeline, the stock fell due to disappointment on the quarterly product mix. Analysts were surprised by the weakness versus consensus for several key growth drivers.
AstraZeneca Shares Drop After Weak Quarterly Print Despite 2024 Growth Guidance -- 2nd Update
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment